What's in Guangdong Raynovent Biotech Co., Ltd's pipeline?

Guangdong Raynovent Biotech Co., Ltd has 22 drugs in our index: 2 marketed, 0 filed, 6 in Phase 3, 1 in Phase 2, 13 in Phase 1.

Which companies overlap with Guangdong Raynovent Biotech Co., Ltd's portfolio?

Top competitors by shared drug class: GlaxoSmithKline, Kissei Pharmaceutical Co., Ltd., Bayer, Eli Lilly and Company, Hanmi Pharmaceutical Company Limited.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/guangdong-raynovent-biotech-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Guangdong Raynovent Biotech Co., Ltd — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Guangdong Raynovent Biotech Co., Ltd pipeline: 2 marketed, 0 filed, 6 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 6 Phase 3 1 Phase 2 13 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Metformin Tablets	Metformin Tablets	marketed
Oseltamivir(oral)	Oseltamivir(oral)	marketed	Neuraminidase inhibitor	Influenza neuraminidase	Infectious Disease
RAY1216	RAY1216	phase 3
Placebo to Oseltamivir	Placebo to Oseltamivir	phase 3	Neuraminidase inhibitor	Influenza neuraminidase	Infectious Disease / Virology
RAY1225	RAY1225	phase 3	FGFR inhibitor	FGFR (Fibroblast Growth Factor Receptor)	Oncology
Placebo to ZSP1273	Placebo to ZSP1273	phase 3	SGLT2 inhibitor	SGLT2	Diabetes
Warfarin Sodium Tablets	Warfarin Sodium Tablets	phase 3	Vitamin K antagonist (coumarin anticoagulant)	Vitamin K epoxide reductase complex 1 (VKORC1)	Cardiovascular
ZSP1273	ZSP1273	phase 3	RNA-dependent RNA polymerase inhibitor	Influenza virus RNA-dependent RNA polymerase	Infectious Diseases

Therapeutic area mix

Cardiovascular · 1
Diabetes · 1
Infectious Disease · 1
Infectious Disease / Virology · 1
Infectious Diseases · 1
Oncology · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

GlaxoSmithKline · 3 shared drug classes
Kissei Pharmaceutical Co., Ltd. · 2 shared drug classes
Bayer · 2 shared drug classes
Eli Lilly and Company · 2 shared drug classes
Hanmi Pharmaceutical Company Limited · 2 shared drug classes
Hoffmann-La Roche · 2 shared drug classes
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 shared drug classes
Pierre Fabre Medicament · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Guangdong Raynovent Biotech Co., Ltd:

Cite this brief

Drug Landscape (2026). Guangdong Raynovent Biotech Co., Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/guangdong-raynovent-biotech-co-ltd. Accessed 2026-05-17.